This pharmacological intervention proves the central role of Ihh in these processes without affecting endogenous bone mass, indicating that Ihh mAb could serve as a potential therapeutic strategy for reducing heterotopic ossification in FOP patients. The gene discussed is IHH; the disease is fibrodysplasia ossificans progressiva.